Cambium Bio Limited
CMB
Rang in Aktien
#32452
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on... Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Aktienkurs
$0.31613178
Zuletzt synchronisiert: 2026-10-21
Marktkapitalisierung
$9.30M
Veränderung (1 Tag)
-0.39%
Veränderung (1 Jahr)
5,893.70%
Land
AU
Handel Cambium Bio Limited (CMB)
Kategorie
Healthcare
Kursverlauf für Cambium Bio Limited (CMB)
Höchster Schlusskurs: $0.01 am 2024-05-01
Niedrigster Schlusskurs: $0.25 am 2013-09-01
Niedrigster Schlusskurs: $0.25 am 2013-09-01
Kursverlauf der Aktie von Cambium Bio Limited von 2013 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2024 | 119.50% |
| 2023 | -92.08% |
| 2022 | -41.49% |
| 2021 | -42.78% |
| 2020 | 56.83% |
| 2019 | -53.42% |
| 2018 | 31.72% |
| 2017 | -21.51% |
| 2016 | 74.18% |
| 2015 | -41.39% |
| 2014 | -67.54% |
| 2013 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $533.52 | 25.11% |
US
|
|
| $183.54 | 583.58% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $887.97 | 9.06% |
NL
|
